N@N

Italian Cancer Center, Ospedali Riuniti, Chooses IntraOp Medical s Mobetron for Advanced Cancer Care

^{Published on 2008-11-25 06:24:34 - Market Wire}
 

SUNNYVALE, Calif.--([ BUSINESS WIRE ])--IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, announced today that it has received an order for the Mobetron from Azienda Ospedaliero-Universitaria "Ospedali Riuniti" Trieste in Northern Italy.

IntraOp's Mobetron is a mobile device that delivers intraoperative electron-beam radiation therapy (IOERT) to a tumor site during cancer surgery. The Mobetron enables radiation and surgical oncologists to target the exact area that requires radiation and to deliver an effective dose of radiation directly to the affected tissue during surgery. Since the Mobetron is a mobile, self-shielded device, doctors will be able to move the Mobetron between operating rooms, avoiding the high cost of outfitting radiation rooms to accommodate traditional linear accelerators. Ospedali Riuniti will use the Mobetron to treat many forms of cancer but have acquired the device to specifically expand their treatment for breast cancer.

The radiotherapy facility at Ospedali Riuniti has been treating patients for over 40 years and has been a leader in implementing new technology for the treatment of cancer. As part of the oncology department, the radiotherapy department currently treats 1000 patients per year, and includes the Radiotherapy Comprehensive Division (Struttura Complessa di Radioterapia). This division deals with all aspects of care for cancer patients, ranging from treatment to medical advice.

Ospedali Riuniti will join a regional program with Centro di Riferimento Oncologico (CRO) in Aviano Italy, in an effort to provide the best cancer treatment possible to the region. CRO adopted the Mobetron in 2007 and is one of the few hospitals in Italy that has been given the status of Institute for Research in the Cure of Cancer and Scientific Study ("IRCSS" - Istituto per la Ricerca e la Cura del Cancro a Carattere Scientifico). Working with CRO will propel Ospedali Riuniti to be a leader in advanced cancer treatments. It will also give patients in the area an opportunity to take advantage of an innovative treatment that can significantly cut down on treatment time and side effects.

Chief Radiology Oncologist Dr. Aulo Beorchia played a key role in helping to bring IOERT and the Mobetron to the facility, and has been a pioneer in bringing the hospital to the forefront of cancer treatment. "We are truly excited to be joining CRO in providing IOERT to our cancer patients," Beorchia said. "Working together, both parties will be able to expand research studies and give more patients the opportunity to receive the best treatment available. This is about quality of care, quality of life and curing the disease."

"Dr. Beorchia and Ospedali Riuniti are passionate and dedicated to the fight against cancer," said John Powers, CEO of IntraOp Medical. "We are glad to see Italy at the forefront of IOERT adaption and helping them to reach many new patients. Ospedali Riuniti has plans to participate with other Mobetron facilities in the Northern Region of Italy in joint trials on advance cancers that are especially well served by the Mobetron."

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company's flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.

For more information about IntraOp Medical and the Mobetron, please visit: [ www.intraopmedical.com ]

For more information about Azienda Ospedaliero-Universitaria "Ospedali Riuniti" Trieste, please visit: [ www.aots.sanita.fvg.it/aots/portale/welcome.asp?lang=2 ]

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.